These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 9552993)

  • 1. Monitoring randomised controlled trials. Parkinson's disease trial illustrates the dangers of stopping early.
    Abrams KR
    BMJ; 1998 Apr; 316(7139):1183-4. PubMed ID: 9552993
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of Parkinson's disease.
    Eadie MJ
    Aust Fam Physician; 1995 Sep; 24(9):1685-7, 1690-2. PubMed ID: 7487655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of early Parkinson's disease: are complicated strategies justified?
    Ahlskog JE
    Mayo Clin Proc; 1996 Jul; 71(7):659-70. PubMed ID: 8656708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug management of Parkinson's disease.
    Kishore A; Snow BJ
    Can Fam Physician; 1996 May; 42():946-52. PubMed ID: 8688697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
    Lees AJ
    BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Formal systematic review of data on patients in all relevant trials is required.
    Counsell C
    BMJ; 1998 Dec; 317(7172):1586. PubMed ID: 9836669
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality.
    Aaltonen H; Kilkku O; Heinonen E; Mäki-Ikola O
    BMJ; 1998 Dec; 317(7172):1586-7. PubMed ID: 9890764
    [No Abstract]   [Full Text] [Related]  

  • 8. [Optimization of the treatment of Parkinson's disease using dopamine agonists].
    Rinne UK
    Arch Neurobiol (Madr); 1991; 54(6):282-7. PubMed ID: 1687430
    [No Abstract]   [Full Text] [Related]  

  • 9. Bromocriptine versus levodopa in early Parkinson's disease.
    Ramaker C; van Hilten JJ
    Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deprenyl and levodopa and Parkinson's disease progression.
    Fowler JS; Fazzini E; Volkow ND
    Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
    Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
    BMJ; 1993 Aug; 307(6902):469-72. PubMed ID: 8400928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and future approaches to therapy.
    Birkmayer W; Birkmayer JD
    Adv Neurol; 1987; 45():511-2. PubMed ID: 3103393
    [No Abstract]   [Full Text] [Related]  

  • 14. Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease.
    Ramaker C; Hilten JJ
    Cochrane Database Syst Rev; 2002; (2):CD003634. PubMed ID: 12076493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selegiline in Parkinson's disease.
    Calne DB
    BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790
    [No Abstract]   [Full Text] [Related]  

  • 16. Selegiline, or the problem of early termination of clinical trials. The clinical questions are not well answered, and probably never will be.
    Breteler MM
    BMJ; 1998 Apr; 316(7139):1182-3. PubMed ID: 9552992
    [No Abstract]   [Full Text] [Related]  

  • 17. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bromocriptine therapy in early-stage Parkinson's disease.
    Fukuyama H; Kawamura J; Akiguchi I; Kimura J; Imai T
    Eur Neurol; 1996; 36(3):164-70. PubMed ID: 8738948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deprenyl in Parkinson's disease.
    Korczyn AD; Nisipeanu P
    Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
    [No Abstract]   [Full Text] [Related]  

  • 20. [Stage-adjusted treatment of idiopathic Parkinson syndrome].
    Ludin HP
    Wien Med Wochenschr; 1995; 145(13):294-8. PubMed ID: 7571654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.